Key insight: Several biotech firms, including BrainStorm, AB Science, and Neuraltus, are forging ahead with drugs to treat aspects of ALS. Scientists are hopeful — but cautious.

Considering it took more than two decades for a second ALS drug to make it to the US market, you might think that few companies are willing to take the risk of developing such treatments.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

    • Out of 60 ALS patients only one had Borrelia but they also had ALS. All had gut yeast infections, 58 had heavy metal toxicity and most had improvements with stem cells. A major problem is cervical osteoarthritis with osteophytes of long duration that when re-injured allows toxins to move from the gut into the CSF

  • The cause of ALS and many other ND is a Borrelia infection. We are wasting Billions of dollars on wrong research.

    • I have ALS and I was told there is nothing that can be done and they just gave me 2 years to live.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy